$OPRX

OptimizeRx (OPRX) partnered with PulsePoint to integrate its EHR and e-prescribing inventory, expected to launch in Nov 2026. This follows a June 2026 network opening. Revenue impact may be revealed in future quarters, according to the company.

Citizens maintained a Market Outperform rating and raised its price target on OptimizeRx (OPRX) to $11, citing digital spend expansion. The firm expects a 12% revenue decline in 2026 due to managed services and macro factors. OPRX reported Q2 2026 adjusted earnings of $0.16 per share, beating estimates, but revenue declined 15% year-over-year. The company has $24.1M in cash and $19.0M in debt, with a strong current ratio of 5.58.

OptimizeRx Corp. integrated its authenticated point-of-care inventory with The Trade Desk's OpenPath, enabling advertisers to access its network of 400+ EHR systems and 800,000 verified HCPs. The move expands healthcare inventory for life sciences advertisers and is expected to launch in Q4 2026.

OptimizeRx (OPRX) reported Q2 2026 revenue of $20.5M, down 30% YoY due to lower-margin services and customer inactivity. Adjusted EBITDA was $4.9M. Full-year guidance was reaffirmed: $95M-$100M revenue and $21M-$25M adjusted EBITDA. AI software revenue grew 25% YoY. Cash and cash equivalents were $24.1M, with debt reduced to $19.7M. Management highlighted strategic shifts and leadership transitions. (350 characters)

OptimizeRx (NASDAQ:OPRX) reported Q2 2026 results with revenue down 30% year over year to $20.5 million. Net revenue retention fell to 90% and a major client generated no revenue. The firm cited $1.7 million severance, a $0.7 million net loss, and adjusted EBITDA of $4.1 million. Debt paydown is prioritized; buybacks possible under a $10 million plan.

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million

OptimizeRx Corp. (Nasdaq: OPRX) appointed Sarah Bast as Chief Marketing Officer. She has over two decades in pharmaceutical marketing, most recently as EVP, Investment Marketplace at Publicis Health Media, with expertise in point of care media and analytics. OptimizeRx said the role will lead marketing strategy and go-to-market initiatives to support product innovation and commercial growth.

OptimizeRx Corp. (Nasdaq: OPRX) launched CopayCue, an enhancement to its Financial Assistance platform that uses real-time, verified HCP prescribing-intent data to display brand copay/affordability offers within e-prescribing workflows. The company says its data shows 4–5% higher prescription lift vs EHR banners and 11.5% average lift for standalone programs.

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001448431 0001448431 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001448431 0001448431 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor